Research analysts at StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN – Get Free Report) in a report released on Saturday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Evogene Stock Down 2.4 %
Shares of NASDAQ EVGN opened at $1.65 on Friday. The firm has a market cap of $8.85 million, a P/E ratio of -0.37 and a beta of 1.36. Evogene has a twelve month low of $1.20 and a twelve month high of $10.40. The company has a 50 day moving average of $1.77 and a 200 day moving average of $3.40.
Institutional Investors Weigh In On Evogene
A hedge fund recently bought a new stake in Evogene stock. Renaissance Investment Group LLC purchased a new stake in shares of Evogene Ltd. (NASDAQ:EVGN – Free Report) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $31,000. Hedge funds and other institutional investors own 10.40% of the company’s stock.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.
Featured Articles
- Five stocks we like better than Evogene
- 5 Top Rated Dividend Stocks to Consider
- Power Up: Gaming Industry Expansion Fuels Stock Opportunities
- Russell 2000 Index, How Investors Use it For Profitable Trading
- These 3 Quirky ETFs May Be Strong Plays in 2025
- About the Markup Calculator
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
